RYTM - リズム・ファ―マシュ―ティカルズ （Rhythm Pharmaceuticals Inc.）

https://www.investing.com/news/pro/rhythm-pharmaceuticals-pt-raised-to-40-at-goldman-sachs-432SI-2988560

- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide -

During the last session, Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)’s traded shares were 0.73 million, with the beta value of the company hitting 1.90. At the end of the trading day, the stock’s price was $29.36, reflecting an intraday loss of -0.91% or -$0.27. The 52-week high for the RYTM share is $34.99, that puts it down … Is Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) Still A Loss Stock Despite Being Up 0.82% YTD? Read More »

https://www.investing.com/news/pro/canaccord-genuity-assumes-rhythm-pharmaceuticals-at-buy-432SI-2982671

The share price of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) fell to $31.25 per share on Friday from $31.70. While Rhythm Pharmaceuticals Inc. has underperformed by -1.42%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RYTM rose by 265.07%, with highs and lows ranging from $34.99 to $3.04, […]

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) concluded the trading at $8.83 on Friday, December 03 with a fall of -4.02% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $9.20 and 5Y monthly beta was reading 1.43 with its price kept floating in the Rhythm Pharmaceuticals Inc. (RYTM) Forecast: Revisiting The Past To Gain Insights For The Future Read More »

Millennium Management LLC lowered its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 13.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,816 shares of the companys stock after selling 23,711 shares during the period. Millennium Management []

Credit Suisse AG trimmed its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.5% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 23,802 shares of the companys stock after selling 1,654 shares during the quarter. Credit Suisse AGs holdings in Rhythm Pharmaceuticals were worth $467,000 []

Charles Schwab Investment Management Inc. raised its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 267,631 shares of the companys stock after acquiring an additional 15,409 shares during the quarter. Charles Schwab Investment Management []

Charles Schwab Investment Management Inc. increased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 267,631 shares of the companys stock after buying an additional 15,409 shares during the period. Charles Schwab Investment Management Inc.s holdings in []

BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 11:20 a.m. ET.

Macquarie Group Ltd. lifted its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 313.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,930 shares of the companys stock after purchasing an additional 1,463 shares during the quarter. Macquarie Group Ltd.s holdings in Rhythm Pharmaceuticals []

Samsara BioCapital LLC increased its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 49.4% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 300,293 shares of the companys stock after purchasing an additional 99,247 shares during the period. Rhythm Pharmaceuticals makes up about 0.7% of Samsara BioCapital []

Rhythm Pharmaceuticals (NASDAQ:RYTM) issued its earnings results on Tuesday. The company reported ($0.70) earnings per share for the quarter, beating the Zacks consensus estimate of ($0.83) by $0.13, MarketWatch Earnings reports. During the same period last year, the firm posted ($0.77) earnings per share. NASDAQ RYTM traded down $0.33 during trading hours on Thursday, reaching []

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $12.10, but opened at $12.64. Rhythm Pharmaceuticals shares last traded at $12.65, with a volume of 706 shares traded. The company reported ($0.70) EPS for the quarter, []